Literature DB >> 8007738

ACAT inhibitors as antiatherosclerotic agents: compounds and mechanisms.

K Matsuda1.   

Abstract

Atherosclerosis is a major death cause in western industrialized countries. A diagnosing system, medical prevention, and treatment of atherosclerosis is not sufficient so far. A direct acting antiatherosclerotic agent is eagerly waited. ACAT inhibitor approach could provide such an agent. In the formation of atherosclerosis, cholesteryl esters, which are the lipids which accumulate in atheromatous plaques by an aid of macrophages and smooth muscle cells, forming foam cells, may play an important role. ACAT enzyme is responsible for the acylation of cholesterol to cholesteryl esters, a transformation which can be essential in not only cholesteryl esters accumulation at arterial walls but also the absorption of cholesterol in the intestine and the excretion of cholesterol in the liver. From these points, ACAT inhibitors might work against atherosclerosis in three different ways: first, cholesteryl ester accumulation inhibition at arterial walls could be a direct antiatherosclerotic effect; second, cholesterol absorption inhibition at the intestine; and third, cholesterol excretion acceleration at the liver, while the later two effects would result in a reduction of blood cholesterol level--a major risk factor of atherosclerosis. Taking account of this discussion, the ACAT inhibitors would be potent antiatherosclerotic agents. Medicinal research has been contributing full strength to produce an ultimate compound. These efforts should provide a drug which will be useful to patients.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8007738     DOI: 10.1002/med.2610140302

Source DB:  PubMed          Journal:  Med Res Rev        ISSN: 0198-6325            Impact factor:   12.944


  8 in total

1.  Pharmacokinetic properties of YM17E, an inhibitor of acyl coenzyme A: cholesterol acyl transferase, and serum cholesterol levels in healthy volunteers.

Authors:  T Uchida; T Usui; T Watanabe; S Higuchi; M Nakata; K Maezawa; Y Kikawa; M Tsunoo; N Nakaya; Y Goto
Journal:  Eur J Clin Pharmacol       Date:  1997       Impact factor: 2.953

2.  Direct effect of an acyl-CoA:cholesterol acyltransferase inhibitor, F-1394, on atherosclerosis in apolipoprotein E and low density lipoprotein receptor double knockout mice.

Authors:  T Chiwata; K Aragane; K Fujinami; K Kojima; S Ishibashi; N Yamada; J Kusunoki
Journal:  Br J Pharmacol       Date:  2001-08       Impact factor: 8.739

3.  Massive xanthomatosis and altered composition of atherosclerotic lesions in hyperlipidemic mice lacking acyl CoA:cholesterol acyltransferase 1.

Authors:  M Accad; S J Smith; D L Newland; D A Sanan; L E King; M F Linton; S Fazio; R V Farese
Journal:  J Clin Invest       Date:  2000-03       Impact factor: 14.808

Review 4.  Macrophage cholesterol homeostasis and metabolic diseases: critical role of cholesteryl ester mobilization.

Authors:  Shobha Ghosh
Journal:  Expert Rev Cardiovasc Ther       Date:  2011-03

5.  Increased atherosclerosis in LDL receptor-null mice lacking ACAT1 in macrophages.

Authors:  S Fazio; A S Major; L L Swift; L A Gleaves; M Accad; M F Linton; R V Farese
Journal:  J Clin Invest       Date:  2001-01       Impact factor: 14.808

Review 6.  Macrophage cholesteryl ester mobilization and atherosclerosis.

Authors:  Shobha Ghosh; Bin Zhao; Jinghua Bie; Jingmei Song
Journal:  Vascul Pharmacol       Date:  2009-10-28       Impact factor: 5.773

7.  Iron-catalyzed urea synthesis: dehydrogenative coupling of methanol and amines.

Authors:  Elizabeth M Lane; Nilay Hazari; Wesley H Bernskoetter
Journal:  Chem Sci       Date:  2018-04-09       Impact factor: 9.825

8.  Biochemical and histopathological study in rats intoxicated with carbontetrachloride and treated with camel milk.

Authors:  Thnaian Althnaian; Ibrahim Albokhadaim; Sabry M El-Bahr
Journal:  Springerplus       Date:  2013-02-18
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.